Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 8, 2003, Pages 1065-1074

  Hawkey, C J ^a   Atherton, J C ^a   Treichel, H C ^a   Thjodleifsson, B ^a   Ravic, M ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ABDOMINAL PAIN; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERADICATION THERAPY; FEMALE; FLU LIKE SYNDROME; HEADACHE; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TASTE DISORDER; ULCER HEALING; UREA BREATH TEST;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; AMOXICILLIN; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CLARITHROMYCIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PEPTIC ULCER; PROTON PUMPS; SAFETY;

EID: 0038368758     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01492.x     Document Type: Article

References (27)

1. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease. J Am Med Assoc 1994; 272: 65-9.
2. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110: 1244-52.
3. Treiber G, Lambert JR. The impact of Helicobacter pylori eradication on peptic ulcer healing. Am J Gastroenterol 1998; 93: 1080-4.
4. Current European concepts in the management of Helicobacter pylori infection: the Maastricht Consensus Report. Gut 1997; 41: 8-13.
5. Soll AH, for the Practice Parameters Committee of the American College of Gastroenterology. Medical treatment of peptic ulcer disease: practice guidelines. J Am Med Assoc 1996; 275: 622-9.
6. Peterson WL, Fendrick AM, Cave DR, Peura DA, Garabedian-Ruffalo SM, Laine L. Helicobacter pylori-related disease: guidelines for testing and treatment. Arch Intern Med 2000; 160: 1285-91.
7. Penston JG, McColl KEL. Eradication of Helicobacter pylori: an objective assessment of current therapies. Br J Clin Phamacol 1997; 43: 223-43.
8. Veldhuyzen van Zanten SJO, Flook N, Chiba N, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Medical Association Journal 2000; 162(12 Suppl.): S3-23.
9. Gisbert JP, González L, Calvet X, et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000; 14: 1319-28.
10. Ohning GV, Barbuti RC, Kovacs TOG, Sytnik B, Humphries TJ, Walsh JH. Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 701-8.
11. Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998; 12: 1079-89.
12. Cloud ML, Enas N, Humphries TJ, Bassion S and the Rabeprazole Study Group. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). Dig Dis Sci 1998; 43: 993-1000.
13. Breiter JR, Riff D, Humphries TJ for the Rabeprazole Study Group. Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease: results of a double-blind, randomized North American study. Am J Gastroenterol 2000; 95: 936-42.
14. Dekkers CPM, Beker JA, Thjodleifsson B, et al. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer - a European multicentre study. Aliment Pharmacol Ther 1998; 12: 789-95.
15. Dekkers CPM, Beker JA, Thjodleifsson B, et al. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. Aliment Pharmacol Ther 1999; 13: 179-86.
16. Stack WA, Knifton A, Thirlwell D, et al. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. Am J Gastroenterol 1998; 93: 1909-13.
17. Miwa H, Ohkura R, Murai T, et al. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection - comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther 1999; 13: 741-6.
18. Miwa H, Yamada T, Sato K, et al. Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 mg and 40 mg rabeprazole with 60 mg lansoprazole. Dig Dis Sci 2000; 45: 77-82.
19. Kihira K, Satoh K, Saifuku K, et al. Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 1083-7.
20. Isomoto H, Furusu H, Morikawa T, et al. 5-Day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 1619-23.
21. Veldhuyzen van Zanten SJO, Bradette M, Farley A, et al. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther 1999; 13: 289-95.
22. Malfertheiner P, Bayerdörffer E, Diete U, et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 1999; 13: 703-12.
23. Lind T, Veldhuyzen van Zanten S, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I study. Helicobacter 1996; 1: 138-44.
24. Gardner J, Sloan S, Barth JA. Onset, duration, and magnitude of gastric antisecretory effects of rabeprazole and omeprazole. Am J Gastroenterol 1999; 94: 2608(Abstract 125).
25. Nagahara A, Miwa H, Ogawa K, et al. Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy. Helicobacter 2000; 5: 88-93.
26. Lueth S, Teyssen S, Singer MV. A four day triple therapy with rabeprazole, amoxycillin and clarithromycin in patients with peptic ulcer disease and Helicobacter pylori infection is safe and effective in 90% - a pilot study. Am J Gastroenterol 2000; 95: 2456(Abstract 157).
27. Mégraud F, Lehn N, Lind T, et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 1999; 43: 2747-52.